Table 1.
Patient characteristics.
| CAP |
NCAP |
ALL |
p value | |
|---|---|---|---|---|
| n = 77 (%) | n = 38 (%) | n = 115 (%) | ||
| age (ys): median (range) | 51 (23–81) | 54.5 (32–80) | 53 (23–81) | 0.1151 |
| menopausal status | 0.3212 | |||
| premenopausal | 40 (51.9) | 16 (42.1) | 56 (48.7) | |
| postmenopausal | 37 (48.1) | 22 (57.9) | 59 (51.3) | |
| setting CT | 0.0712 | |||
| neoadjuvant | 51 (66.2) | 26 (68.4) | 77 (67) | |
| adjuvant | 20 (26) | 9 (23.7) | 29 (25.2) | |
| palliativ | 6 (7.8) | 3 (7.9) | 9 (7.8) | |
| tumour features | ||||
| subtype | 0.6613 | |||
| invasive ductal | 69 (89.6) | 36 (94.7) | 105 (91.3) | |
| invasive lobular | 4 (5.2) | 1 (2.6) | 5 (4.35) | |
| other | 4 (5.2) | 1 (2.6) | 5 (4.35) | |
| grading | 0.032 | |||
| 1 | 6 (7.8) | 1 (2.6) | 7 (6.1) | |
| 2–3 | 71 (92.2) | 37 (97.4) | 108 (93.9) | |
| estrogen receptor | 0.3152 | |||
| positive | 50 (64.9) | 21 (55.3) | 71 (61.7) | |
| negative | 27 (35.1) | 17 (44.7) | 44 (38.3) | |
| progesterone receptor | 0.5532 | |||
| positive | 47 (61) | 21 (55.3) | 68 (59.1) | |
| negative | 30 (39) | 17 (44.7) | 47 (40.9) | |
| HER2-status | 0.1602 | |||
| positive | 27 (35.1) | 8 (21.1) | 35 (30.4) | |
| negative | 48 (62.3) | 30 (78.9) | 78 (67.8) | |
| unknown | 2 (2.6) | 0 | 2 (1.7) | |
| Ki 67 status | 0.8792 | |||
| <20% | 17 (22) | 10 (26.3) | 27 (23.5) | |
| >20% | 58 (75.3) | 27 (71) | 85 (73.9) | |
| unknown | 2 (2.7) | 1 (2.6) | 3 (2.6) | |
| tumour size | 0.9972 | |||
| pT1 | 35 (45.5) | 17 (44.7) | 52 (45.2) | |
| pT 2-3 | 40 (51.9) | 20 (52.7) | 60 (52.2) | |
| pT unknown | 2 (2.6) | 1 (2.6) | 3 (2.6) |
1 = Mann-Whitney-U-Test; 2 = Chi2-Test; 3 = Fishers' Exact test.
CAP = intervention group; CT = chemotherapy; HER2 = human epidermal growth factor receptor 2; NCAP = control group; ys = years.